PLYMOUTH MEETING, PA--(Marketwire - November 8, 2010) -  Marvin H. Berman, PhD, CBT, BCN, a clinician in private practice and founder and president of Quietmind Foundation (QMF), announces the formation of Quietmind Associates (QMA), a professional association providing testing and drug-free interventions and counseling for brain disorders and peak performance. QMA and QMF are located in Plymouth Meeting, PA. Dr. Berman has more than 30 years' experience in private practice, including over 10 years delivering biofeedback/neurofeedback.

QMA and QMF welcomes Jack Lebeau, M.D., FACC, a staff member at Abington Hospital, as new Medical Director for both groups. Dr. Lebeau now oversees all clinical and research activities at QMA and QMF while providing physical and neurological evaluations. Dr. Lebeau is very interested in the mind-body relationship and sees neurofeedback and the other tools at QMA and QMF as highly promising treatments for a wide range of brain disorders.

We have also added the following staff members:
Mark M. Berman, Psy.D., a clinical psychologist and certified neurofeedback practitioner with particular expertise in using biofeedback to treat substance abuse and aging-related problems, including cognitive impairment and dementia.

David B. Yaden, CHt., a certified hypnotherapist who will provide hypnotherapy, counseling, health education, and consultation services.

With expanded staff, QMA can now offer clients a range of noninvasive treatment options for ADD/ADHD, depression, PTSD, dementias, and learning disorders as well as brain training for peak academic, musical, and athletic performance.

Quietmind Foundation, a 501(c)3 nonprofit founded in 2000, is an international center for cutting-edge research and consultation in use of brainwave (EEG) biofeedback and related technologies. Its research focuses on dementia, learning disabilities, and brain injury with a goal to integrate innovative technologies and evidence-based behavioral interventions into governmental, public health, and educational service delivery systems.

QMF's research on Alzheimer's disease was accepted for presentation at the July 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria. This research demonstrated improvements in subjects' memory, executive function, and psychiatric symptoms, and a reduction in medications. Dr. Berman and QMF will soon be announcing the start of another clinical trial for treating early-stage dementia, using infrared light simulation.

Contact Information:

For more information, contact:
Marvin H. Berman, Ph.D., CBT, BCN
Principal, Quietmind Associates
President, Quietmind Foundation
Psychotherapy, Assessment, Neurofeedback, Consultation,
and Applied Clinical Research
521 Plymouth Road, Suite 111
Plymouth Meeting PA 19462
T: 610-940-0488
F: 215-359-0630